Andere talen Cutia Therapeutics

Aandelen

2487

KYG2606C1006

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:22 20-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,22 ^HKD	-3,86%		+0,97%	-43,35%

31/05	Cutia Therapeutics presenteert de resultaten van het fase III klinische onderzoek naar acne op het Aziatische Dermatologiecongres	MT
30/05	Cutia Therapeutics krijgt goedkeuring voor klinische studie in China voor geneesmiddel tegen dermatitis	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Certain Ordinary Shares of Cutia Therapeutics are subject to a Lock-Up Agreement Ending on 11-JUN-2024.	11/06
Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress	31/05
Cutia Therapeutics Obtains Clinical Trial Approval in China for Dermatitis Drug	30/05
Cutia Therapeutics Announces Investigational New Drug Application of CU-10101 for Atopic Dermatitis Approved by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China	30/05
Cutia Therapeutics' Unit Receives Jiangsu Drug Manufacturing Certificate	30/04
Cutia Therapeutics Submits NDA for Androgenetic Alopecia Treatment Spray; Shares Jump 6%	30/04
Cutia Therapeutics Submits New Drug Application for Cu-40102 (Topical Finasteride Spray) in Hong Kong, PRC	30/04
Cutia Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Cutia Therapeutics' Atopic Dermatitis Drug's IND Application Accepted by China's NMPA	27/03
Cutia Therapeutics Announces the Investigational New Drug Application of CU-10101 (Topical Novel Small Molecule Agent) for the Treatment of Mild to Moderate Atopic Dermatitis Accepted by the Center for Drug Evaluation of the National Medical Products Administration	26/03
Cutia Therapeutics Included in Two FTSE Indices	18/03
Cutia Therapeutics Announces Completion of Phase I Clinical Trial of CU-20401	27/02
Cutia Therapeutics Included in Hang Seng Family of Indexes	20/02
Cutia's Phase 3 Clinical Trial for Analgesic Cream Reaches Primary Endpoint; Shares Surge 12%	31/01
China Accepts Cutia Therapeutics's New Drug Application for Alopecia Treatment; Shares Surge 13%	31/01
Cutia Therapeutics Announces New Drug Application for CU-40102 (Topical Finasteride Spray) Accepted by the National Medical Products Administration	30/01
Cutia Therapeutics Doses First Patient for Anti-Obesity Injectable	03/01
Cutia Therapeutics Announces First Patient Enrollment in the Phase II Clinical Trial of CU-20401	02/01
Cutia Therapeutics Publishes Results of Phase 3 Trial for Alopecia, Acne Treatments in China	11/12
Cutia Therapeutics Announces Results of Phase III Clinical Trials of CU-40102 (Topical Finasteride Spray) and CU-10201 (Topical 4% Minocycline Foam) in the People's Republic of China	11/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cutia Therapeutics

Aandelen

2487

KYG2606C1006

Andere talen

Filters